Study Confirms: Shorter DR-TB Regimens Save Lives and Budgets

A new study confirms that six-month BPaL/M regimens for drug-resistant TB save lives and money. Compared to longer treatments, they cut costs per cure, boost completion rates, and are projected to deliver nearly US$1 billion in economic benefits in South Africa and US$800 million in the Philippines within five years.